On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Annals of Oncology, sous presse, 2020, article en libre accès
Résumé en anglais
Recently, Montopoli et al evaluated the relationship between androgen-deprivation therapy (ADT) for prostate cancer (PC) and risk of infection by SARSCoV-2 through a population-based study of patients with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto (1). They found that only four out of 5,273 PC patients treated with ADT (0.07%) developed SARS-CoV-2 infection and such patients had a significantly lower risk of SARS-CoV-2 infection than the patients who did not receive ADT. (...)
